Type 1 diabetes treatment could be revolutionized by solving one of transplant medicine's most persistent challenges: keeping newly transplanted insulin-producing cells alive long enough to function effectively. Current stem cell-derived beta cell transplants often fail because the cells suffocate in their new environment, lacking the immediate blood supply needed for survival. A breakthrough approach addresses this fundamental limitation by pre-building vascular networks before transplantation occurs. Scientists developed a three-dimensional scaffold system that cultures stem cell-derived beta cells alongside endothelial cells and fibroblasts for precisely three days. This brief co-culture period allows the formation of rudimentary blood vessel networks that persist after transplantation and accelerate the establishment of proper blood flow. The timing proves critical—seven days of pre-culture actually compromised insulin secretion despite better cell survival, while three days achieved the optimal balance. Transplant recipients showed measurably reduced fasting glucose levels, indicating functional insulin production from the engineered tissue constructs. This vascularization strategy represents a significant advance in regenerative diabetes treatment, potentially making stem cell therapies more reliable than current cadaveric islet transplants. The research addresses a core engineering challenge in tissue transplantation: how to prevent the inevitable cell death that occurs when living tissues are moved to oxygen-poor environments. While promising, the approach requires refinement—the scaffolds still face integration challenges at extrahepatic sites, and long-term durability remains unproven. Nevertheless, this work provides a viable pathway toward more successful beta cell replacement therapy.